

Clinicians' Case Book

STELFONTA[®] (tigilanol tiglate injection)



For more information contact
Virbac at 1-800-338-3659

IMPORTANT SAFETY INFORMATION

Accidental self-injection of STELFONTA may cause severe wound formation. To decrease the risk of accidental self injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit <https://vet-us.virbac.com/stelfonta>




STELFONTA[®]
(tigilanol tiglate injection)

Prescribing information



**Shaping the future
of animal health**

Explore mast cell tumor (MCT) treatment cases in different locations:




Upper forelimb




Tucker, 8-year-old Staffordshire Bull Terrier, 7.2cm³ subcutaneous mast cell tumor (MCT) on elbow. US.



Mirage, 12-year-old Jack Russell Terrier, 3.3cm³ subcutaneous MCT on front leg (carpus). Australia.



Wilbur, 6.5-year-old Pyrenees mix, 4.15cm³ subcutaneous MCT on inner elbow. US.




Paula, 8.5-year-old Jack Russell Terrier, 0.5cm³ subcutaneous MCT on elbow. Australia.



Upper hindlimb

Roo, 12-year-old mixed breed, 2.7cm³ cutaneous mast cell tumor (MCT) on right hind thigh. Australia.



Dale, 11-year-old Bassett Hound, 9.4cm³ cutaneous MCT on right back hip (stifle). US.



Peaches, 10-year-old mixed breed, 5.5cm³ cutaneous MCT on inner back leg (medial stifle). Australia.



Puddles, 4-year-old, Miniature Pinscher, 1.4cm³ cutaneous MCT on inner back leg (medial stifle). Australia.



Head (nose, ear, eye)


Brooklyn, 6-year-old mixed breed, 0.42cm³ cutaneous mast cell tumor (MCT) on base of ear. US.



Buster, 6-year-old Chihuahua cross, 1.1cm³ cutaneous MCT on ear. Australia.



Buddy, 11-year-old Boxer cross, 0.94cm³ cutaneous MCT on nose. US.



Mariah, 4-year-old Wolfhound cross, 0.1cm³ cutaneous MCT on muzzle. Australia.




Paw




Zazzy-lou, 7-year-old Boxer, 3.7cm³ cutaneous mast cell tumor (MCT) on dorsal paw. US.



Coco, 4-year-old Pug, 0.35cm³ subcutaneous MCT on dorsal paw. UK.



Eliza, 10-year-old mixed breed, 3.2cm³ subcutaneous MCT on upper dorsal paw. US.



Indra, 8-year-old Bernese Mountain Dog, cutaneous MCT on paw. Germany.


Christiane Bracke




Body (flank, chest and abdomen)



Boe, 8-year-old Staffordshire Bull Terrier, 3.15cm³ cutaneous mast cell tumor (MCT) on thorax. UK.




Wader, 9-year-old Mastiff, 4.3cm³ cutaneous MCT on abdomen. Australia.



Jute, 10-year-old Cattle Dog, small (0.2cm³) cutaneous MCT on abdomen. Australia.




Lianie, 4-year-old Basenji, 9.6cm³ cutaneous MCT on abdomen. US.



Tail and genitals


Rosie 3-year-old Boxer, a 0.3cm³ cutaneous mast cell tumor (MCT) on tail. Australia.

 QBiotics Group




Piper 9-year-old Cross breed, 0.2cm³ cutaneous MCT on penis (prepuce). Australia.

 QBiotics Group



Violette 8-year-old Dachshund, 0.6cm³ cutaneous MCT on vulva. Australia.

 QBiotics Group



Biscuit, 10-year-old Staffordshire Bull Terrier, 0.1cm³ cutaneous MCT on perianal region. Australia.

 QBiotics Group

